Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

Evercore ISI analysts cautioned investors, writing Thursday that “with regards to current headlines, we see no meaningful ...

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

Moderna (NASDAQ:MRNA) shares climbed 10% on Thursday as concerns mounted over a hantavirus outbreak connected to a cruise ship.

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...

The results are part of the company’s strategy to “diversify our geographic footprint” and rely less on the US market, Chief ...

By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...

These are strong results, and would likely make it hard for the FDA to refuse in a way that withstands arbitrary and capricious review,” said Dorit Reiss, a vaccine policy expert ...

Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its COVID-19 vaccine in international markets, ‌sending its shares up nearly 5% in ...

Vertex Pharmaceuticals halted a cystic fibrosis program in the works with Moderna over lung inflammation concerns. The ...